Tuesday May 2, 12:03 pm Eastern Time
Company Press Release
Axiom Biotechnologies Receives Notice of Allowance on
Two Patents for Cell-Based Compound Profiling
SAN DIEGO--(BW HealthWire)--May 2, 2000--Axiom Biotechnologies Inc. today
announced that it has received Notice of Allowance from the United States Patent and
Trademark Office on two U.S. patent applications for instrumentation and methods relating
to pharmacology profiling of compounds in cell-based assays. The two Allowed patent applications will expand the Company's
patent portfolio by protecting the use of flow-based analytical systems for profiling compounds on living cells using a variety of
cell-based approaches to assess receptor pharmacology, mechanism of action and toxicity endpoints.
``These two Allowances further reinforce Axiom's position as a leader in cell-based analyses for post-screening compound
profiling,'' said Pandi Veerapandian, President & Chief Scientific Officer. ``We are particularly pleased to extend and protect
our flow-based approaches beyond fluorimetry into flow cytometry where the company can perform high efficiency analyses of
cultured cell populations, as well as patient cell samples for pharmacogenomic applications.''
The titles of the two patent applications are, ``Apparatus and Method for Compound Profiling of Living Cells,'' and ``Cell Flow
Apparatus and Method for Real-Time Measurements of Cellular Response,'' and the Company expects these patents to issue
later this year.
Axiom Biotechnologies is a privately-held biotechnology company focused on improving the efficiency of drug discovery by
accelerating the process of lead profiling by applying an array of proprietary ``hits-to-leads'' technologies and assays. The
company's patented flagship technology, the High Throughput Pharmacology System (HT-PS), combines proprietary natural
cell-based assays, high throughput automated instrumentation and novel pharmacoinformatics and biomining tools to assess and
prioritize potential lead compounds based on their functional pharmacological properties. Through collaborations with
pharmaceutical and biotechnology companies, Axiom is committed to becoming the pharmaceutical industry's partner of choice
in high throughput pharmacology.
Contact:
Axiom Biotechnologies
Stephen Eisold, Chief Executive Officer, 858/455-4500
www.axiombio.com |
